Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Neuro-Oncology|July 23, 2011
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomasMatthew L Bush, Janet Oblinger, Victoria Brendel, et al.
Oncotarget|April 22, 2017
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cellsAlejandra M Petrilli, Jeanine Garcia, Marga Bott, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma ModelSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Laryngoscope Investigative Otolaryngology|October 20, 2021
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomasD Bradley Welling, Katharine A Collier, Sarah S Burns, et al.
Nature Communications|February 11, 2026
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing lossSimeng Lu, Zhenzhen Yin, Limeng Wu, et al.
Neuro-Oncology|July 9, 2018
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningiomaSteven P Angus, Janet L Oblinger, Timothy J Stuhlmiller, et al.
Science Advances|November 2, 2022
Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancyLai Man Natalie Wu, Feng Zhang, Rohit Rao, et al.
Neuro-Oncology|January 8, 2019
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance developmentMarisa A Fuse, Christine T Dinh, Jeremie Vitte, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 5